Principal Analyst, Datamonitor Healthcare
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Amanda Micklus
As the pipeline and market for novel cell and gene therapies expands, it is time for drug developers to address other critical aspects in the logistical chain – and for these complex therapies a lot of those issues relate to manufacturing. Looking at specific cases, In Vivo has underlined the main manufacturing challenges facing cell and gene therapy developers, and highlighted methods and approaches being used to generate solutions.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2018.
Even though 2018 did not feature the big influx of biopharma M&A that was expected, there were still encouraging signs that major advancements and breakthroughs in the biotech industry attract buy-outs. Cancer-focused companies and oncology assets again drove volume in alliances and financing transactions.
AstraZeneca completed another divestment, this time selling the RSV product Synagis to Swedish Orphan Biovitrum for $2.3 billion. Boston Scientific paid just over $4 billion for interventional device company BTG. Biopharma and device financing were down.
Third quarter device financing totaled $2.6 billion, a 24% decrease from the $3.4 billion brought in during Q2. The change partially stems from a sharp decline in debt financing. During the third quarter, debt raises brought in $258 million, just 10% of the Q3 total, while in the previous quarter, aggregate debt (at $947 million) represented 28% of the financing total.
J&J and Lilly each penned $3.7 billion RNAi alliances, with Arrowhead and Dicerna, respectively. Novartis made another move into radiopharmaceuticals with the $1.9 billion buy of Endocyte. Over $1 billion was raised through biopharma IPOs.